Health Equity: Implications for Developing and Developed Countries

The global pandemic has put a strain on healthcare services across the world but its complications have been far worse in poorer countries. Sebnem Kalemli-Ozcan, Neil Moskowitz Professor of Economics at the University of Maryland joined Kamalini Ramdas, Professor of Management Science and Operations and Deloitte Chair in Innovation and Entrepreneurship at London Business School to discuss innovative solutions to healthcare challenges in developing countries and the economic case for global vaccinations. Moderated by Elias Papaioannou, Professor of Economics at London Business School and co-Academic Director at the Wheeler Institute for Business and Development.

0:00 Intro
4:25 Kalemli-Ozcan’s new research: The Economic Case for Global Vaccinations
13:20 Kalemli-Ozcan shares the total cost of vaccination in 3 different scenarios
16:49 Ramdas on health equity
29:33 Kalemli-Ozcan on which sectors will be most affected in rich and developing countries
38:11 Ramdas on pooling to mitigate the cost of testing
42:29 Ramdas on telehealth
47:27 Ramdas on shared medical appointments
49:00 Kalemli-Ozcan on controlling the pandemic
51:30 Ramdas on controlling the pandemic
53:19 Kalemli-Ozcan on the impact of her research
55:07 Ramdas on the way forward after the pandemic

Follow our social media accounts:

#wheelerinstitute #lbs #londonbusinessschool

[sirisaksirisak]

Sound little echo sir. In productivity processing there're defected finished product about 2-3% in product line though setting the control points.If there're no defective in product line show that that has something wrong in that product lot.(Quality control chart).However in vaccinating we serius in human life priority.